leisure time -WSS

leisure time

author：explore 2025-09-06 03:27:58 - browse：6

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： More regulation could be coming for drug ads

explore

WSS

Lab trade group sues FDA to halt regulation of lab

In venture capital firm's success, lessons for turning crisis into profit

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

Astronauts get first look at the spacecraft that will fly them around the moon

Hospitals use virtual reality to design more inclusive rooms for kids

Report: NIH

entertainment

leisure time

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Choosing scientific sides in the fight against Alzheimer's

As demand for Covid shots wanes, Moderna seeks its next success

Former Georgia lieutenant governor says he received grand jury subpoena

Jerome Adams on the need for new antivirals for Covid

Addiction doctors spar with methadone clinics over legislation

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Germany receives 178 compensation applications from gay servicepeople over discrimination

Duchenne breakthrough therapy leaves behind pioneering families

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

explore

Akili, maker of video game for ADHD, to be acquired for 34 million

First Opinion Podcast: What happens when kids become caregivers?

Discs beat pads, tampons for heavy menstrual flow, new study shows

In venture capital firm's success, lessons for turning crisis into profit

Ohioans vote in high

Scientists successfully use ultrasound imaging to map brain activity

explore

hotspot

explore

leisure time